Biotech "Tweets of the Week" for July 6-10, 2015Dare we say, a slow news week?
Featuring: $VRTX $ESPR $NVS $SGYP $EPZM $CELG $GILD $XBI $IBB Check out the Biotech Tweets of the Week archive. |
|
$VRTX
halted, news pending
— Tom Wrigley (@WrigleyTom) July 2, 2015
$VRTX Orkambi Approval a 'De-Risking' Event for Vertex, Leerink Partners Says; PT to $158 http://t.co/45He1gWFEV via @Street_Insider
— BioBreakout (@BioBreakout) July 6, 2015
When thinking about the price of #Orkambi ask yourself honestly: at what price would you rather have the drug than the cash?
— Oli Rayner (@oli_rayner) July 3, 2015
@jeanmi5557 in biotech I like mike king JMP & Michael yee from RBC leerink team very good also IMHO GS in biotech worst.
— dougheuring (@dougheuringaria) July 5, 2015
Asfotase Alfa was approved in Japan. Which gives yet another excuse to tweet out this amazing photo. $ALXN pic.twitter.com/GWwG8uhgZu
— Brad Loncar (@bradloncar) July 6, 2015
$VRTX Orkambi Approval a 'De-Risking' Event for Vertex, Leerink Partners Says; PT to $158 http://t.co/45He1gWFEV via @Street_Insider
— BioBreakout (@BioBreakout) July 6, 2015
with DB left out of the $AXON IPO party, RBC fills their role with a $150 upside target in the 'blue sky' scenario
— zach (@zbiotech) July 6, 2015
@PropThinker and with these news I am back in $MRNS
— Alfredo Fontanini (@AF_biotech) July 6, 2015
Nice2see $ENTA +3% on day $GILD gets Japan apprvl4 Harvoni. $ABBV/ $ENTA expect Japan decision re GT1 4Q15 &sep submission4 GT2 b4 yr-end.
— Roy Friedman (@DewDiligence) July 6, 2015
This preliminary prospectus was submitted to SEC today. It does not constitute an offer of any securities for sale. http://t.co/egDnCp6wfe
— Brad Loncar (@bradloncar) July 6, 2015
Paging @dbsable — I believe $ETRM is about to violate your clean balance sheet rule.
— Adam Feuerstein (@adamfeuerstein) July 6, 2015
@srqstockpicker nope. $QURE is the only company to sign an exclusive agreement that I am aware of.
— Zack (@BioTerp) July 6, 2015
$SMMT is one that has had strong institutional holdings as of late. Low float play w/ good cash position. #Duchenne stock.
— Sheff (@SheffStation) July 7, 2015
$ESPR removal of 240mg partial hold
— zach (@zbiotech) July 7, 2015
@Festo50 I thought it was a huge turd. The brilliant thing they did was control all managed care issues by having all scripts go thru them
— DeadCatBill (@getbillasap) July 7, 2015
$DEPO bid almost 29...$HZNP what 's your next bid price?
$ENDP....crickets???
— happyycamperr (@happyycamperr) July 7, 2015
$PBMD covered the balance. It's getting pumped by chats. +$500 in the trade.
— Rick (@Skipjackrick) July 7, 2015
It's not a great sign how these companies in the middle of deals ( $HZNP, $AET, $JUNO, etc) have been trading down.
— Brad Loncar (@bradloncar) July 7, 2015
..and CNBC parades out all technicians..and Ralph Acampora goes on a tweetfest... and ppl bearish for past 8 years pull out their charts.
— Colfax (@ColfaxCapital) July 7, 2015
@23aloha @IncredibleTrade may be run-up to Ph II data that was due mid-2015 $FATE
— elbertos (@elbertos) July 7, 2015
$BLUE Baillie Gifford reports 10.34% stake
— Bio Stocks™ (@BioStocks) July 7, 2015
@zzlangerhans $abio & $adhd too. We'll have to see? That $achn buy in the $2-3 range was brilliant. They are quite the contrarians.
— Joe (@Drchik23) July 7, 2015
— BioBreakout (@BioBreakout) July 7, 2015
$NVS heart failure drug Entresto approved -- will they strike the outcomes-based payments deals they were considering piloting pre approval?
— Sarah Karlin (@SarahKarlin) July 7, 2015
.@BioBounce @rajramaswamy I agree, there is nothing wrong with selling, then buying back higher. Took me a while to learn this skill.
— E B (@Mazmasta) July 7, 2015
Due to current work situation, will continue to be mostly offline for a while; meanwhile, my favorite bio setup $REGN pic.twitter.com/r0lIn6oELU
— CR (@CashRocket) July 8, 2015
I miss talking about #biotech
— Dan Rosenblum (@sharkbiotech) July 8, 2015
@adamfeuerstein hired same reason companies raise cash right before sale. To put themselves in better negotiating position:-)
— NathanAaron (@NathanAhron) July 8, 2015
@amitp_gupta should be
— Red Acre Investments (@redacre) July 8, 2015
The CCO hire hurting $SGYP today more than the $IRWD data
— Vikram Khanna (@VikramKhanna_) July 8, 2015
@DewDiligence GenSight Biologics. They just filed their F1:
http://t.co/GwgwHLqmtC
— Zack (@BioTerp) July 8, 2015
Been speaking to quite a few companies in the IPO queue- certainly a different tone from 3 months ago
— Vikram Khanna (@VikramKhanna_) July 8, 2015
@PropThinker they created a nice buying oppy in $BLUE though :)
— Ponty (@pbmech) July 8, 2015
$AKAO - Daily hammer candle forming.
— Brandon Hayward (@VexTrades) July 8, 2015
if biotech isn't in a bubble - should it trade in a vacuum? isolated from the rest of the economy?
— zach (@zbiotech) July 8, 2015
Less than 10% of the 400+ biotech stocks I tracked were green today. That's as low a number as I can recall offhand.
— David Miller (@AlpineBV_Miller) July 8, 2015
Morning! I'll be tweeting today over @FDAadcomm about the ODAC for $LLY's #necitumumab. It'll be a condensed meeting from 8:30 am - 12:30pm.
— Jessica Adams (@RxRegA) July 9, 2015
"Announces Results" is a cousin to "Provides Update." $AQXP
— Brad Loncar (@bradloncar) July 9, 2015
$RARE 99.02
Ultragenyx Releases Positive Interim 40-Week Bone Treatment Data From Ongoing Pediatric Phase 2 S...
http://t.co/L8BL645wxH
— Tom Wrigley (@WrigleyTom) July 9, 2015
The top 10 biotech drugs in 2014 by revenue --> >$78 B WW http://t.co/OcdyJi9Rfa @NatureBiotech pic.twitter.com/03ICFlmaOJ
— Eric Topol (@EricTopol) July 9, 2015
$EPZM Announces Extension Of $CELG Research Collaboration
— Bio Stocks™ (@BioStocks) July 9, 2015
@mikegoodma @dougheuringaria $EPZM just got EZH2 back, I seriously doubt they want to give it right back to someone else.
— David Sobek (@dsobek) July 9, 2015
. @zbiotech Back in February, UBS’ Roden predicted $PBYI would be acquired before ASCO at > $330 per share.
— Adam Feuerstein (@adamfeuerstein) July 9, 2015
$BLCM broke IPO price. Been completely pummeled since lockup expired. Nearly half its market cap is in cash now.
— PropThink (@PropThinker) July 9, 2015
Can't escape science - Henry Moore bone sculpture in the middle of Kensington Gardens: pic.twitter.com/IsYLhbOlxq
— Sally Church (@MaverickNY) July 9, 2015
Spending bills put @NIH on track for biggest raise in 12 years
http://t.co/qH9Mk4YGHu pic.twitter.com/iq3buHZIlk
— Science Magazine (@sciencemagazine) July 9, 2015
@mcuban Model had been that GH turns on IGF1 which then mediates effect of GH at distance. Too simple. GHR and IGF1R need each other
— Ethan Weiss (@ethanjweiss) July 9, 2015
@mcuban Anytime. I sometimes forget that there are not just scientists out there who care about science. Thanks for reminding me...
— Ethan Weiss (@ethanjweiss) July 9, 2015
Loving $SRPT today, #independence ranks #1 on the list of #DMD young men. Austin demonstrating something #NEVERDONE http://t.co/3j9t6waSIi
— Christine McSherry (@fundDuchenne) July 9, 2015
@srqstockpicker The issue is $IBB as a sector hasnt experienced a sell off like $SMH.. if market doesnt goto ATH soon, $IBB < 350
— OptionEdgeSeeker (@TradeTexasBig) July 9, 2015
The $XBI is much stronger than the $IBB $SPY & $IWM today .. #Biotech still the best place in the market for your $$$
— Joe (@GantosJ) July 9, 2015
This bill promises to speed up drug approvals so much that it's making people uncomfortable http://t.co/Bqf2cjCxra by @carolynyjohnson
— Matthew Herper (@matthewherper) July 9, 2015
$EPZM Doses First Patient in Five-Arm Phase 2 Study For Tazemetostat http://t.co/mKOuas30NB
— Bio Stocks™ (@BioStocks) July 9, 2015
$ESRX says it's hard to implement the pay-for-performance model that $NVS is proposing for Entresto
http://t.co/85MfxzDzUe
— Caroline Chen (@CarolineYLChen) July 9, 2015
Sold half $afmd earlier 15.94 from 6.10, this one payed no attention to China or Greece. Beast. Letting rest ride to infinity.
— Pawcio (@pawcio2009) July 9, 2015
@DrSManian lol do we still need a suicide switch ? :-)
— Raj R (@rajramaswamy) July 9, 2015
$CLVS Underwriters exercise option in full to buy additional shares from offering. Not surprising given the discount.
— Juan P. Serrate, DVM (@JPZaragoza1) July 10, 2015
@sharkbiotech @megtirrell @matthewherper had us not changed inversion laws $gild would have bought a euro bio by now I m sure
— shmittahcapital (@ymscapital) July 10, 2015
Typically good @LifeSciVC piece on #biotech volatility. Imp to know where you live on the trader/investor continuum. http://t.co/KjFFbtdtbn
— David Sable (@dbsable) July 10, 2015